Regular ArticleHormone Replacement Therapy Formulations and Risk of Epithelial Ovarian Carcinoma
References (50)
Estrogen replacement therapy and risk of epithelial ovarian cancer
Gynecol Oncol
(1996)- et al.
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study
Obstet Gynecol
(1997) - et al.
A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer
J Clin Epidemiol
(2000) - et al.
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis
Obstet Gynecol
(1998) The etiology and prevention of ovarian cancer
Am J Obstet Gynecol
(1975)Incessant ovulation—A factor in ovarian neoplasia?
Lancet
(1971)- et al.
Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro
Am J Obstet Gynecol
(1995) - et al.
Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth
Gynecol Oncol
(1992) Menopause and hormone replacement therapy: An overview
Obstet Gynecol
(1996)- et al.
The effect of postmenopausal estrogen therapy on bone mineral density in elderly women
N Engl J Med
(1993)
Post menopausal estrogen and progestin use and the risk of cardiovascular disease
N Engl J Med
Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis
Br J Obstet Gynaecol
Determinants of ovarian cancer risk. I. Reproductive experience and family history
J Natl Cancer Inst
Reproductive variables, tobacco, ethanol, coffee, and somatometry as risk factors for ovarian cancer
Int J Cancer
Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies, II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group
Am J Epidemiol
Noncontraceptive estrogen use and epithelial ovarian cancer
Am J Epidemiol
An epidemiologic study of epithelial carcinoma of the ovary
Am J Epidemiol
Risk factors for ovarian cancer: A case-control study
Br J Cancer
Noncontraceptive estrogen use and the occurrence of ovarian cancer
J Natl Cancer Inst
Menopause and ovarian cancer
Am J Epidemiol
Ovarian cancer: Incidence and case-control study
Cancer
Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies
Int J Cancer
Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism
Cancer Epidemiol Biomarkers Prev
Estradiol and progesterone receptors in normal ovary and ovarian tumors
Acta Obstet Gynecol Scand
Cited by (60)
Menopause and Aging
2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth EditionMenopause and Aging
2013, Yen and Jaffe's Reproductive Endocrinology: Seventh EditionMenopause and aging
2009, Yen & Jaffe's Reproductive Endocrinology: Expert Consult - Online and PrintMenopause and Aging
2009, Yen & Jaffe's Reproductive EndocrinologyEstrogen and progestogen therapy in postmenopausal women
2008, Fertility and SterilityCitation Excerpt :Increased duration of ET use for 10 or more years was associated with a significantly increased risk of ovarian cancer (RR 1.8; 95% CI, 1.1–3.0). In a 2002 American case-control study, adjusted ORs for invasive epithelial ovarian cancer were 0.90 (95% CI, 0.61–1.33) with ever-use of conjugated estrogens and 0.52 (95% CI, 0.25–1.10) with other estrogens (109). Odds ratios for HT with ever-use of progestogens combined with conjugated estrogens and other estrogens were 1.06 (95% CI, 0.74–1.52) and 1.08 (95% CI, 0.59–2.00), respectively.
Hormone replacement therapy and ovarian cancer risk: A meta-analysis
2008, Gynecologic OncologyCitation Excerpt :Nineteen case–control studies were included in our meta-analysis (involving 8240 case patients and 20,996 control subjects). Table 2 summarizes the characteristics of these case–control studies [37–55]. Since too few studies are evaluating current or former hormone use, we just calculated the summary estimate of ever HRT use.